The　hCDR1　is　a　synthetic　peptide　based　on　the　complementarity　determining　region　1　of　an　autoantibody　and　ameliorates　serological　and　clinical　manifestations　of　lupus　in　NZB/W　F1　mice.　This　study　aimed　to　determine　the　potential　effects　of　hCDR1　in　SLE-like　chronic　graft　versus　host　disease　(cGVHD)　mouse　model.　We　found　that　hCDR1　administrated　by　gavage　had　no　significant　effect　on　the　disease　progression　in　SLE-cGVHD　mice.　However,　hCDR1　administrated　by　subcutaneous　injection　exacerbated　the　lupus-like　disease　manifested　by　earlier　onset　of　proteinuria,　elevated　serum　levels　of　autoantibodies,　more　immune　complex　deposition　in　the　kidney　and　severe　kidney　injury　in　SLE-cGVHD　mice.　SLE-cGVHD　mice　that　received　hCDR1　by　subcutaneous　injection　also　exhibited　significant　increase　of　CD4+　Treg　cells　proportion.　This　study　demonstrated　that　hCDR1　administrated　through　subcutaneous　injection　but　not　gavages　slightly　aggravated　the　disease　in　SLE-cGVHD.